Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Establish an appropriate administration schedule for oxaliplatin in mfolfox in patients on hemodialysis: an evidence-based approach
- At: 2017 FIP Congress in Seoul (South Korea)
- Type: Poster
- By: YEH, Hui-Yin (En Chu Kong Hospital, New Taipei City, China Taiwan)
- Co-author(s): Hui-Yin Yeh: Department of Pharmacy, En Chu Kong Hospital, New Taipei City, Taiwan, Province of China
Chia-Hua Lee: Department of Pharmacy, En Chu Kong Hospital, New Taipei City, Taiwan, Province of China
BackgroundOxaliplatin is mainly eliminated by the kidneys, and its clearance strongly correlates with glomerular filtration rate. However, there is no consensus about the optimal dose adjustment of oxaliplatin and timing of dialysis session in patients on hemodialysis.
PurposeTo establish an appropriate administration schedule for oxaliplatin in.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019